We strive to be a global biopharma leader whose mission is
to develop innovative, life-changing medicine
We focus on improving patients' quality of life through the development of innovative drugs for diseases with high unmet needs.
improving quality of life.
Established in 2000 and publicly traded since 2006 (KOSDAQ), CrystalGenomics is Korea's leading biopharma company, deeply invested in developing new drugs. Our drug discovery program is driven by our core technologies: Soluble Protein Solution (SPS™) - to identify the structure of target proteins for intervention and Structural ChemoProteomics (SCP™) - to efficiently identify potential novel drug leads.
Our drugs candidates are internally developed using our proprietary structure-based drug design and enabling us to possess exclusive rights. Strategic collaborations and alliances with multinational pharmaceutical partners then allows us to capitalize and bring our drug candidates to the global market.
Our first approved drug is Acelex (polmacoxib), a next-gen tissue-specific nonsteroidal anti-inflammatory drug for the treatment of osteoarthritis and the first new chemical entity approved in Korea. Further development programs for Acelex include expanding into new indications and markets.
and its core technology platform.
It is a leader in the Korean biopharmaceutical industry.
1st in Korea
First research team from Korea to publish a Nature cover story
1.5 Trillion Won
Experience with exporting / licensing deals - Combined total value of recent deals for Acelex (966.6 Billion Won) and CG-806 (4,874 Billion Won) is ~1.5 Trillion Won
Research driven workforce - 95% of CrystalGenomics' workforce consists of life science professionals with Masters and Ph.D.s
Next-gen Biopharma leader - Moving into the future to become a biopharmaceutical R&D technology leader.
We are a publicly traded company, listed on the KOSDAQ